TICKERNERD
Menu
PHATPHATHealthcare · Biotechnology

PHAT Stock Forecast: Phathom Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$7.40
+5.71% on the day

The 12 Wall Street analysts covering Phathom Pharmaceuticals, Inc. hold a median 12-month price target of $21 — +183.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$566.3M
Ticker Nerd rank
82 / 100
Median analyst target
$21
Analysts covering
12
Revenue$74.3M+88.0% y/y
Operating income−$4.0M
Net income−$17.6M
Free cash flow−$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.7%
1M
−14.7%
YTD
−55.4%
1Y
−40.8%
From 52W high
−59.1%
From 52W low
+10.4%
$7
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHAT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phathom Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Quality
86
Value
84
Volatility
70
Issuance
69
Accruals
64
Size
50
Revisions
40
Momentum
34

Growth (96): Sales and profits are climbing, and climbing faster than before.

Momentum (34): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PHAT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHAT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26PHATHigh $29Median $21Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $10Median $21High $29

The green dot is the last close — the median target sits +183.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
9 Sept 2026Leerink PartnersInitiatesMarket Perform$10
17 Aug 2026BarclaysMaintainsOverweight$18 → $14
17 Aug 2026BarclaysMaintainsOverweight—
31 July 2026GuggenheimMaintainsBuy$25 → $22
31 July 2026GuggenheimMaintainsBuy—
31 July 2026HC Wainwright & Co.ReiteratesBuy$26
31 July 2026HC Wainwright & Co.ReiteratesBuy—
30 July 2026NeedhamMaintainsBuy—
30 July 2026NeedhamMaintainsBuy$28 → $22
17 June 2026HC Wainwright & Co.ReiteratesBuy—
17 June 2026HC Wainwright & Co.ReiteratesBuy$26
27 Mar 2026BarclaysUpgradeOverweight—
27 Feb 2026GuggenheimMaintainsBuy—
9 Dec 2025BarclaysInitiatesEqual-Weight—
31 Oct 2025HC Wainwright & Co.MaintainsBuy—
9 June 2025Craig-HallumMaintainsBuy—
9 June 2025HC Wainwright & Co.ReiteratesBuy—
6 June 2025NeedhamMaintainsBuy—
2 May 2025Craig-HallumMaintainsBuy—
2 May 2025Goldman SachsMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHAT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PHAT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Phathom Pharmaceuticals, Inc. returned −40.8% against +17.5% for the S&P 500, dividends included.

PHAT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26PHATS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PHAT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Phathom Pharmaceuticals, Inc. (PHAT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.3×

Cheaper than 86% of US stocks

Price / sales
2.4×

Cheaper than 47% of US stocks

Price / book
−1.7×

Cheaper than 95% of US stocks

EV / EBITDA
−23.6×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
88.0%

Higher than 91% of US stocks

Earnings growth (YoY)
88.0%

Higher than 82% of US stocks

Gross margin
79.7%

Higher than 90% of US stocks

Operating margin
−5.3%

Higher than 27% of US stocks

Net margin
−41.3%

Higher than 11% of US stocks

Returns & dividend
Return on equity
50.5%

Higher than 93% of US stocks

Return on assets
−8.8%

Higher than 28% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Phathom Pharmaceuticals, Inc. (PHAT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Phathom Pharmaceuticals, Inc. has a market value of $566.3M and an enterprise value of $946.4M.

  • Revenue in the twelve months to 30 June 2026: $239.7M. The latest quarter grew 88.0% year on year.

  • Net income over the same four quarters: −$99.1M, a −41.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.28.

  • Free cash flow in the twelve months to 30 June 2026: −$36.9M.

  • Shares outstanding: 80.1M.

  • Trailing P/E: −2.3×; forward P/E: 6.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Phathom Pharmaceuticals, Inc. employs 371 people — $646K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

PHAT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PHATPhathom Pharmaceuticals, Inc.$566.3M
82
CRMDCorMedix, Inc.$576.0M
61
SLDBSolid Biosciences, Inc.$574.5M
43
CLYMClimb Bio, Inc.$589.2M
66
PRMEPrime Medicine, Inc.$567.7M
40
NVCTNuvectis Pharma, Inc.$567.5M
65
OLMAOlema Pharmaceuticals, Inc.$592.7M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phathom Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PHAT news & analysis

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

GlobeNewsWire · 8 Oct 2026positive

Phathom Pharmaceuticals announced it will present three scientific analyses of VOQUEZNA (vonoprazan) at the ACG 2026 Annual Scientific Meeting. The presentations will cover real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis.

Why it matters — The presentations will provide additional analyses of VOQUEZNA in GERD for investors following Phathom’s product and clinical evidence.

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

GlobeNewsWire · 29 Sept 2026positive

Phathom Pharmaceuticals announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed investigational dosing regimen of VOQUEZNA tablets in adults with Non-Erosive GERD. Topline results are expected in the first quarter of 2028, and the study, if successful, is intended to support a potential VOQUEZNA label expansion for as-needed treatment of heartburn in NERD patients.

Why it matters — The study advances a potential labeling expansion for VOQUEZNA into an as-needed NERD treatment regimen, a use for which PPIs are not currently approved in the U.S., building on positive Phase 2 data.

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Business Wire · 16 Sept 2026negative

SBS Law announced that Phathom Pharmaceuticals (PHAT) investors have an opportunity to join a fraud investigation into the company. The notice, issued via Business Wire, invites qualifying investors to participate in the investigation.

Why it matters — A fraud investigation involving the company could signal legal or regulatory concerns for PHAT shareholders.

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case

Seeking Alpha · 9 Sept 2026positive

Phathom Pharmaceuticals is executing a specialist-focused strategy targeting gastroenterologists to drive adoption of VOQUEZNA. Second-quarter 2026 revenue grew 88% to $74.3M, while SG&A declined, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, indicating operating leverage, though revenue-interest financing remains a material risk.

Why it matters — PHAT watchers would care because the report highlights strengthening specialist-driven demand, solid revenue growth, and improving operating leverage that support the company's path toward sustainable profitability, while noting the lingering financing risk.

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Phathom Pharmaceuticals announced that members of its management team are scheduled to participate in upcoming investor conferences in September. The company, which focuses on developing treatments for gastrointestinal diseases, shared this schedule in a press release.

Why it matters — These investor conference appearances give PHAT watchers an opportunity to hear directly from management about the company's operations and strategy.

FAQ

Frequently asked questions about PHAT stock

What is the PHAT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Phathom Pharmaceuticals, Inc. have a median 12-month price target of $21, with estimates ranging from $10 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PHAT stock a buy right now?

Of the 12 analysts covering Phathom Pharmaceuticals, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phathom Pharmaceuticals, Inc. 82 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHAT?

As at 14 Oct 2026, Phathom Pharmaceuticals, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will PHAT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +183.8% from the last close, and Ticker Nerd's factor model ranks Phathom Pharmaceuticals, Inc. 82 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PHAT stock forecast for 2030?

No analyst covering Phathom Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $29 over the next 12 months.

How has PHAT stock performed over the past year?

Phathom Pharmaceuticals, Inc. returned -40.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phathom Pharmaceuticals, Inc. do?

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases.

What is the latest news on PHAT?

The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting". Phathom Pharmaceuticals announced it will present three scientific analyses of VOQUEZNA (vonoprazan) at the ACG 2026 Annual Scientific Meeting. The presentations will cover real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis.

Company

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s commercial portfolio centers on vonoprazan-based therapies, including VOQUEZNA for the relief of heartburn associated with non-erosive and erosive GERD and the healing and maintenance of erosive GERD in adults. It also markets VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for the treatment of Helicobacter pylori infection in adults. Phathom Pharmaceuticals operates as a specialist in acid-related GI disorders, combining research, product development, and commercialization to address conditions that affect the digestive system.

CEO Mr. Steven L. Basta M.B.A. · 371 employees · United States · https://www.phathompharma.com